Development and validation of an affinity chromatography step using a peptide ligand for cGMP production of factor VIII.
An affinity chromatography step was developed for purification of recombinant B-Domain Deleted Factor VIII (BDDrFVIII) using a peptide ligand selected from a phage display library. The peptide library had variegated residues, contained both within a disulfide bond-constrained ring and flanking the ring. The peptide ligand binds to BDDrFVIII with a dissociation constant of approximately 1 microM both in free solution and when immobilized on a chromatographic resin. The peptide is chemically synthesized and the affinity resin is produced by coupling the peptide to an agarose matrix preactivated with N-hydroxysuccinimide. Coupling conditions were optimized to give consistent and complete ligand incorporation and validated with a robustness study that tested various combinations of processing limits. The peptide affinity chromatographic operation employs conditions very similar to an immunoaffinity chromatography step currently in use for BDDrFVIII manufacture. The process step provides excellent recovery of BDDrFVIII from a complex feed stream and reduces host cell protein and DNA by 3-4 logs. Process validation studies established resin reuse over 26 cycles without changes in product recovery or purity. A robustness study using a factorial design was performed and showed that the step was insensitive to small changes in process conditions that represent normal variation in commercial manufacturing. A scaled-down model of the process step was qualified and used for virus removal studies. A validation package addressing the safety of the leached peptide included leaching rate measurements under process conditions, testing of peptide levels in product pools, demonstration of robust removal downstream by spiking studies, end product testing, and toxicological profiling of the ligand. The peptide ligand affinity step was scaled up for cGMP production of BDDrFVIII for clinical trials.
Kelley
Brian D
BD
Wyeth BioPharma, 1 Burtt Rd., Andover, Massachusetts 01810, USA. BKelley@wyeth.com
Tannatt
Molly
M
Magnusson
Robert
R
Hagelberg
Sigrid
S
Booth
James
J
D000818:Animals; D016466:CHO Cells; D002846:Chromatography, Affinity / Q000295:instrumentation / Q000379:methods*; D002847:Chromatography, Agarose / Q000295:instrumentation / Q000379:methods*; D045424:Complex Mixtures / Q000737:chemistry / Q000302:isolation & purification; D006224:Cricetinae; D003412:Cricetulus; D006152:Cyclic GMP / Q000737:chemistry; D005169:Factor VIII / Q000737:chemistry* / Q000235:genetics / Q000302:isolation & purification*; D006801:Humans; D008024:Ligands; D019151:Peptide Library; D010455:Peptides / Q000737:chemistry*; D011485:Protein Binding; D011994:Recombinant Proteins / Q000737:chemistry / Q000302:isolation & purification; D014771:Virion / Q000737:chemistry / Q000302:isolation & purification
D045424:Complex Mixtures; D008024:Ligands; D019151:Peptide Library; D010455:Peptides; D011994:Recombinant Proteins; D005169:Factor VIII; D006152:Cyclic GMP